Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Purchase, New York, focused on developing innovative small molecule therapies for age-related neurodegenerative diseases and retinal disorders. With a strong commitment to improving cognitive health and visual function in the aging population, the company is addressing significant unmet medical needs in these critical areas. Cognition Therapeutics utilizes its proprietary drug design technologies to advance a robust pipeline aimed at delivering transformative treatments, thereby establishing itself as a key player in the biopharmaceutical sector. As the demand for effective solutions in neurodegeneration and vision impairment rises, Cognition is well-positioned to make a meaningful impact on patient outcomes. Show more

Location: 2500 WESTCHESTER AVE., PURCHASE, NY, UNITED STATES, 10577, Purchase, NY, 10577, USA | Website: https://www.cogrx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

96.22M

52 Wk Range

$0.22 - $3.83

Previous Close

$1.24

Open

$1.23

Volume

2,083,284

Day Range

$1.08 - $1.26

Enterprise Value

57.26M

Cash

39.82M

Avg Qtr Burn

-5.651M

Insider Ownership

0.85%

Institutional Own.

25.20%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Zervimesine (CT1812) Details Alzheimer's disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zervimesine (CT1812) Details Early Alzheimer's disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zervimesine (CT1812) Details Alzheimer's disease	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zervimesine (CT1812) Details Dementia	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.